## ALNY: Alnylam Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.3% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($379.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Bernstein lowers Alnylam stock price target to $491 on slowing Amvuttra sales**
- Source: Investing.com | 20260106T140943 | Neutral | Relevance: 100%
- Bernstein SocGen Group has reduced its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) to $491 from $525 due to a perceived slowdown in Amvuttra sales, particularly for ATTR-CM. Despite the lowered target, it remains significantly above the current trading price. The firm forecasts fourth-quarter 2025 Amvuttra sales below consensus, though Alnylam's overall revenue growth remains strong, and the company recently reported robust third-quarter financial results.

**2. Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference**
- Source: Business Wire | 20260105T140912 | Bullish | Relevance: 100%
- Alnylam Pharmaceuticals, Inc. announced that its management will present a company overview and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The company plans to unveil its new five-year strategy, provide an update on Q4 and full-year 2025 global net product revenues, and share an outlook for 2026 product sales. A live audio webcast will be available on the Investors section of Alnylam's website.

**3. Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference**
- Source: Yahoo Finance Australia | 20260105T150943 | Somewhat-Bullish | Relevance: 100%
- Alnylam Pharmaceuticals, Inc. announced it will webcast a presentation and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company plans to unveil its new five-year strategy, provide an update on fourth quarter and full year 2025 global net product revenues, and give a 2026 product sales outlook. A live audio webcast will be available on Alnylam's website.

**4. Western Financial Corp CA Invests $1.24 Million in Alnylam Pharmaceuticals, Inc. $ALNY**
- Source: MarketBeat | 20260104T130834 | Neutral | Relevance: 100%
- Western Financial Corp CA recently invested $1.24 million in Alnylam Pharmaceuticals (NASDAQ:ALNY), acquiring 2,724 shares. Despite some insider selling, analysts maintain a "Moderate Buy" rating with a consensus target price of $477.44. The company, which specializes in RNA interference therapeutics, has seen significant institutional ownership.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Leerink Partner | $351 | $370 | -5% |
| 2025-12-11 | Stifel | $508 | $495 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Leerink Partner | main | Market Perform |
| 2025-12-11 | Stifel | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.03M) |
| Sells | 3 ($0.83M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- FMR, LLC: 12.7% (+6.1%)
- Capital World Invest: 12.4% (-2.2%)
- Vanguard Group Inc: 10.3% (+2.0%)
- Blackrock Inc.: 7.5% (-0.8%)
- JPMORGAN CHASE & CO: 6.9% (+340.7%)

### Key Risks

1. Near-term weakness: 6.0% below SMA50 despite long-term uptrend.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +4.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 36.8x attractive for 123% earnings growth. Quality metrics strong (ROE 33%). Balance sheet: strong liquidity (2.5x). Revenue growth strong at 46% YoY. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $53.7B |
| Beta | 0.32 |
| 52W Range | $205.87 - $495.55 |
| Short Interest | 4.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.49 |
| Forward P/E | 36.8 |
| Current P/E | 81.9 |
| YoY Growth | 122.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -4.3% to 0.3% (+4.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.6pp (needs >4.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. MACD histogram positive (1.96), confirming momentum. RSI neutral at 45. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.35% (CS: 43) | Neutral |
| RSI_14 | 45.4 | Neutral |
| MACD Histogram | 1.96 | Bullish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 0.940x | Below |
| vs SMA200 | 1.088x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $406.40
- **Stop Loss:** $379.38 (6.6% risk)
- **Target:** $433.42 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 48
- **Position Value:** $19,507.20
- **Portfolio %:** 19.51%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-12 (Est: $1.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.75 | $2.90 | +66.1% |
| 2025Q2 | $0.15 | $0.32 | +119.6% |
| 2025Q1 | $-0.37 | $-0.01 | +97.3% |
| 2024Q4 | $-0.14 | $0.06 | +142.5% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*